Results 251 to 260 of about 1,101,401 (313)

No evidence for genotype-treatment interactions with breast cancer endocrine therapy adverse effects in UK Biobank. [PDF]

NPJ Breast Cancer
Mokbel K, Weedon MN, Moye V, Ruth KS, Jackson L.   +4 more
europepmc   +1 more source

Erratum for the Research Article "AND-1 is a critical regulator of R-loop dynamics and a target to overcome endocrine resistance" by Z. Li <i>et al</i>.

Sci Adv
europepmc   +1 more source

Thyroid and cortisol endocrinopathies and survival in cancer patients treated with immune checkpoint inhibitors in UAE. [PDF]

J Endocr Soc
Alqedra M, Fahmayee B, Wahba L, Ansari J, Govender RD, Al-Shamsi S, Almazrouei R.   +6 more
europepmc   +1 more source

Chromatin architecture reprogramming reveals novel epigenetic dependencies in breast cancer. [PDF]

Genes Dev
Garcia-Martinez L, Zha M, Borges RL, Liu T, González-Blanco G, Martinez Alonso A, Stransky S, Sidoli S, Zhu H, Wang Z, Morey L.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Endocrine Rhythms

Acta Clinica Belgica, 1979
info:eu-repo/semantics ...
Désir, Daniel, Vanhaelst, Luc
openaire   +3 more sources

Telomerase in endocrine and endocrine-dependent tumors

The Journal of Steroid Biochemistry and Molecular Biology, 2001
Telomerase, the ribonucleoprotein enzyme that elongates chromosomal ends, or telomeres, is repressed in most normal somatic cells but reactivated in transformed cells to compensate for the progressive erosion of the telomeres during cell divisions. In accordance with this hypothesis, the presence of telomerase activity has been reported in more than 90%
ORLANDO, CLAUDIO, GELMINI, STEFANIA
openaire   +3 more sources